1
|
Marani LO, Costa AFO, Kuznetsova V, Faria JTB, Garcia CAB, Scheucher PS, Schiavinato J, Lima ASG, Welner R, Madeira MIA, Gloria ABF, Fagundes EM, Nunes EC, Higashi M, Duarte BK, Pagnano KB, Traina F, Rego EM, Figueiredo-Pontes LL. A EXPRESSÃO DIFERENCIAL DE CÉLULAS PROGENITORAS LEUCÊMICAS DEFINIDAS POR CD99/CD123 ESTÁ ASSOCIADA À MUTAÇÃO FLT3-ITD E RECAÍDA NA LEUCEMIA MIELOIDE AGUDA. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
2
|
Costa AFO, Kuznetsova V, Marani LO, Lopes IA, Binelli LS, Scheucher PS, Schiavinato JL, Madeira MIA, Pagnano KBB, Duarte BK, Glória ABF, Rego EM, Traina F, Welner R, Figueiredo-Pontes LL. IMBALANCED ACTIVATING AND INHIBITORY RECEPTORS ON CD56DIM NATURAL KILLER CELLS PREDICTS POOR OUTCOMES IN ACUTE MYELOID LEUKEMIA. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
3
|
Marani LO, Garcia CAB, Lopes I, Costa AFO, Madeira MIA, Binelli LS, Schiavinato JL, Scheucher PS, Silva FB, Lima ASG, Fagundes ABFG, Maranhão E, Higashi M, Kerbauy F, Ayoub FL, Duarte BK, Pagnano KB, Traina F, Rego EM, Figueiredo-Pontes LL. ANORMALIDADES 3Q E DESREGULAÇÃO DE EVI1 EM LEUCEMIA MIELOIDE AGUDA: DO DIAGNÓSTICO AO DESFECHO CLÍNICO. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
4
|
de Almeida LY, Pereira-Martins DA, Weinhäuser I, Ortiz C, Cândido LA, Lange AP, De Abreu NF, Mendonza SES, de Deus Wagatsuma VM, Do Nascimento MC, Paiva HH, Alves-Paiva RM, Bonaldo CCOM, Nascimento DC, Alves-Filho JC, Scheucher PS, Lima ASG, Schuringa JJ, Ammantuna E, Ottone T, Noguera NI, Araujo CL, Rego EM. The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells. Front Oncol 2021; 11:686445. [PMID: 34650910 PMCID: PMC8506138 DOI: 10.3389/fonc.2021.686445] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Accepted: 09/06/2021] [Indexed: 11/23/2022] Open
Abstract
In approximately 15% of patients with acute myeloid leukemia (AML), total and phosphorylated EGFR proteins have been reported to be increased compared to healthy CD34+ samples. However, it is unclear if this subset of patients would benefit from EGFR signaling pharmacological inhibition. Pre-clinical studies on AML cells provided evidence on the pro-differentiation benefits of EGFR inhibitors when combined with ATRA or ATO in vitro. Despite the success of ATRA and ATO in the treatment of patients with acute promyelocytic leukemia (APL), therapy-associated resistance is observed in 5-10% of the cases, pointing to a clear need for new therapeutic strategies for those patients. In this context, the functional role of EGFR tyrosine-kinase inhibitors has never been evaluated in APL. Here, we investigated the EGFR pathway in primary samples along with functional in vitro and in vivo studies using several APL models. We observed that total and phosphorylated EGFR (Tyr992) was expressed in 28% and 19% of blast cells from APL patients, respectively, but not in healthy CD34+ samples. Interestingly, the expression of the EGF was lower in APL plasma samples than in healthy controls. The EGFR ligand AREG was detected in 29% of APL patients at diagnosis, but not in control samples. In vitro, treatment with the EGFR inhibitor gefitinib (ZD1839) reduced cell proliferation and survival of NB4 (ATRA-sensitive) and NB4-R2 (ATRA-resistant) cells. Moreover, the combination of gefitinib with ATRA and ATO promoted myeloid cell differentiation in ATRA- and ATO-resistant APL cells. In vivo, the combination of gefitinib and ATRA prolonged survival compared to gefitinib- or vehicle-treated leukemic mice in a syngeneic transplantation model, while the gain in survival did not reach statistical difference compared to treatment with ATRA alone. Our results suggest that gefitinib is a potential adjuvant agent that can mitigate ATRA and ATO resistance in APL cells. Therefore, our data indicate that repurposing FDA-approved tyrosine-kinase inhibitors could provide new perspectives into combination therapy to overcome drug resistance in APL patients.
Collapse
Affiliation(s)
- Luciana Yamamoto de Almeida
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.,Center for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Diego A Pereira-Martins
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.,Center for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil.,Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Isabel Weinhäuser
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.,Center for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil.,Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - César Ortiz
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.,Center for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Larissa A Cândido
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.,Center for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Ana Paula Lange
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil
| | - Nayara F De Abreu
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil
| | - Sílvia E S Mendonza
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.,Center for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Virgínia M de Deus Wagatsuma
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.,Center for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Mariane C Do Nascimento
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.,Center for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Helder H Paiva
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.,Center for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Raquel M Alves-Paiva
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.,Center for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
| | | | - Daniele C Nascimento
- Department of Pharmacology, University of Sao Paulo, Ribeirao Preto Medical School, Ribeirao Preto, Brazil
| | - José C Alves-Filho
- Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Priscila S Scheucher
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil
| | - Ana Sílvia G Lima
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil
| | - Jan Jacob Schuringa
- Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Emanuele Ammantuna
- Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Tiziana Ottone
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy.,Santa Lucia Foundation, I.R.C.C.S., Neuro-Oncohematology, Rome, Italy.,Hematology Division, Laboratórios de Investigação Médica 31 (LIM 31), Faculdade de Medicina, University of Sao Paulo, Sao Paulo, Brazil
| | - Nelida I Noguera
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
| | - Cleide L Araujo
- Center for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Eduardo M Rego
- Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.,Center for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil.,Hematology Division, Laboratórios de Investigação Médica 31 (LIM 31), Faculdade de Medicina, University of Sao Paulo, Sao Paulo, Brazil
| |
Collapse
|
5
|
Marani LO, Costa AFO, Silva FB, Madeira IA, Scheucher PS, Schiavinato JL, Lima ASG, Dorê A, Pagnano KBB, Duarte BK, Kerbauy F, Feliciano JV, Higashi M, Bittencourt R, Nunes EC, Glória ABF, Fagundes E, Fraga ES, Traina F, Rego EM, Freeman S, Figueiredo-Pontes LL. UNRAVELLING THE HIGH INCIDENCE OF ACUTE MYELOID LEUKEMIA WITH MONOCYTIC BLAST DIFFERENTIATION IN A BRAZILIAN MULTICENTER STUDY. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Marani LO, Costa AFO, Silva FB, Madeira MIA, Scheucher PS, Schiavinato JL, Lima ASG, Pagnano KBB, Duarte BK, Freeman S, Traina F, Rego EM, Figueiredo-Pontes LL. ABSENT CD33 IN AML PATIENT MIMICS MRD POSITIVE: A SINGLE CASE REPORT. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Gutierrez-Rodrigues F, Alves-Paiva RM, Scatena NF, Martinez EZ, Scheucher PS, Calado RT. Association between leukocyte telomere length and sex by quantile regression analysis. Hematol Transfus Cell Ther 2021; 44:346-351. [PMID: 33593713 PMCID: PMC9477766 DOI: 10.1016/j.htct.2020.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Revised: 11/20/2020] [Accepted: 12/03/2020] [Indexed: 12/02/2022] Open
Abstract
Introduction Telomere length (TL) is a biomarker of cellular proliferative history. In healthy individuals, leukocyte TL shortens with age and associates with the lifespan of men and women. However, most of studies had used linear regression models to address the association of the TL attrition, aging and sex. Methods We evaluated the association between the TL, aging and sex in a cohort of 180 healthy subjects by quantile regression. The TL of nucleated blood cells was measured by fluorescent in situ hypridization (flow-FISH) in a cohort of 89 men, 81 women, and 10 umbilical cord samples. The results were validated by quantitative polymerase chain reaction (qPCR) and compared to a linear regression analysis. Results By quantile regression, telomere dynamics slightly differed between sexes with aging: women had longer telomeres at birth and slower attrition rate than men until the sixth decade of life; after that, TL eroded faster and became shorter than that in men. These differences were not observed by linear regression analysis, as the overall telomere attrition rates in women and men were similar (42 pb per year, p < 0.0001 vs. 45 pb kb per year, p < 0.0001). Also, qPCR did not recapitulate flow-FISH findings, as the telomere dynamics by qPCR followed a linear model. Conclusion The quantile regression analysis accurately reproduced a third-order polynomial TL attrition rate in both women and men, but it depended on the technique applied to measure TL. The Flow-FISH reproduced the expected telomere dynamics through life and, differently from the qPCR, was able to detect the subtle TL variations associated with sex and aging.
Collapse
Affiliation(s)
| | | | - Natália F Scatena
- Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil
| | - Edson Z Martinez
- Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil
| | - Priscila S Scheucher
- Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil
| | - Rodrigo T Calado
- Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil
| |
Collapse
|
8
|
Quintino de Oliveira B, Catto LFB, Santana BAA, Tellechea MF, Scheucher PS, Scheinberg P, Calado RT. Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia. Br J Haematol 2020; 193:410-414. [PMID: 33216370 DOI: 10.1111/bjh.17140] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Accepted: 09/09/2020] [Indexed: 12/23/2022]
Abstract
Eltrombopag has been added to first-line treatment of immune aplastic anaemia (AA), resulting in higher responses. We analysed marrow samples of AA patients who responded to immunosuppressive therapy (IST) alone or in combination with eltrombopag for the composition of the haematopoietic stem and progenitor cell (HSPC) compartment. The number of CD34+ cells and multipotent progenitors was higher in patients treated with eltrombopag (P < 0·005; P < 0·05; respectively), but not the number of stem cells. No aberrant phenotype was observed. These results indicate that eltrombopag augments CD34+ cells in vivo and preferentially expands multipotent progenitors, but not stem cells.
Collapse
Affiliation(s)
- Bruno Quintino de Oliveira
- Department of Medical Imaging, Haematology, and Clinical Oncology, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil
| | - Luiz F B Catto
- Department of Medical Imaging, Haematology, and Clinical Oncology, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil
| | - Bárbara A A Santana
- Department of Medical Imaging, Haematology, and Clinical Oncology, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil
| | - M Florencia Tellechea
- Department of Medical Imaging, Haematology, and Clinical Oncology, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil
| | - Priscila S Scheucher
- Department of Medical Imaging, Haematology, and Clinical Oncology, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil
| | - Phillip Scheinberg
- Division of Haematology, Hospital A Beneficência Portuguesa, São Paulo, SP, Brazil
| | - Rodrigo T Calado
- Department of Medical Imaging, Haematology, and Clinical Oncology, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil
| |
Collapse
|
9
|
Lange AP, Almeida LY, Araújo Silva CL, Scheucher PS, Chahud F, Krause A, Bohlander SK, Rego EM. CCAAT/enhancer-binding protein alpha (CEBPA) gene haploinsufficiency does not alter hematopoiesis or induce leukemia in Lck-CALM/AF10 transgenic mice. ACTA ACUST UNITED AC 2019; 52:e8424. [PMID: 31141090 PMCID: PMC6542091 DOI: 10.1590/1414-431x20198424] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Accepted: 03/15/2019] [Indexed: 12/31/2022]
Abstract
Although rare, CALM/AF10 is a chromosomal rearrangement found in immature T-cell acute lymphoblastic leukemia (T-ALL), acute myeloid leukemia, and mixed phenotype acute leukemia of T/myeloid lineages with poor prognosis. Moreover, this translocation is detected in 50% of T-ALL patients with gamma/delta T cell receptor rearrangement, frequently associated with low expression of transcription factor CCAAT/enhancer-binding protein alpha (CEBPA). However, the relevance of CEBPA low expression for CALM/AF10 leukemogenesis has not yet been evaluated. We generated double mutant mice, which express the Lck-CALM/AF10 fusion gene and are haploinsufficient for the Cebpa gene. To characterize the hematopoiesis, we quantified hematopoietic stem cells, myeloid progenitor cells, megakaryocyte-erythrocyte progenitor cells, common myeloid progenitor cells, and granulocyte-macrophage progenitor cells. No significant difference was detected in any of the progenitor subsets. Finally, we tested if Cebpa haploinsufficiency would lead to the expansion of Mac-1+/B220+/c-Kit+ cells proposed as the CALM/AF10 leukemic progenitor. Less than 1% of bone marrow cells expressed Mac-1, B220, and c-Kit with no significant difference between groups. Our results showed that the reduction of Cebpa gene expression in Lck-CALM/AF10 mice did not affect their hematopoiesis or induce leukemia. Our data corroborated previous studies suggesting that the CALM/AF10 leukemia-initiating cells are early progenitors with lymphoid/myeloid differentiating potential.
Collapse
Affiliation(s)
- A P Lange
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - L Y Almeida
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - C L Araújo Silva
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - P S Scheucher
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - F Chahud
- Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - A Krause
- Laboratório de Análises Clínicas Veterinárias, Universidade Federal de Santa Maria, Santa Maria, RS, Brasil
| | - S K Bohlander
- Leukaemia & Blood Cancer Research Unit, Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand
| | - E M Rego
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Divisão de Hematologia, LIM31, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| |
Collapse
|
10
|
Lucena-Araujo AR, Coelho-Silva JL, Pereira-Martins DA, Thomé C, Scheucher PS, Lange AP, Paiva HH, Hemmelgarn BT, Morais-Sobral MC, Azevedo EA, Franca-Neto PL, Franca RF, Silva CL, Krause A, Rego EM. ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype. Oncotarget 2018; 8:8475-8483. [PMID: 28035072 PMCID: PMC5352415 DOI: 10.18632/oncotarget.14295] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Accepted: 11/30/2016] [Indexed: 12/11/2022] Open
Abstract
Here, we evaluated whether the overexpression of transcriptionally inactive ΔNp73 cooperates with PML/RARA fusion protein in the induction of an APL-leukemic phenotype, as well as its role in vitro in proliferation, myeloid differentiation, and drug-induced apoptosis. Using lentiviral gene transfer, we showed in vitro that ΔNp73 overexpression resulted in increased proliferation in murine bone marrow (BM) cells from hCG-PML/RARA transgenic mice and their wild-type (WT) counterpart, with no accumulation of cells at G2/M or S phases; instead, ΔNp73-expressing cells had a lower rate of induced apoptosis. Next, we evaluated the effect of ΔNp73 on stem-cell self-renewal and myeloid differentiation. Primary BM cells lentivirally infected with human ΔNp73 were not immortalized in culture and did not present significant changes in the percentage of CD11b. Finally, we assessed the impact of ΔNp73 on leukemogenesis or its possible cooperation with PML/RARA fusion protein in the induction of an APL-leukemic phenotype. After 120 days of follow-up, all transplanted mice were clinically healthy and, no evidence of leukemia/myelodysplasia was apparent. Taken together, our data suggest that ΔNp73 had no leukemic transformation capacity by itself and apparently did not cooperate with the PML/RARA fusion protein to induce a leukemic phenotype in a murine BM transplantation model. In addition, the forced expression of ΔNp73 in murine BM progenitors did not alter the ATRA-induced differentiation rate in vitro or induce aberrant cell proliferation, but exerted an important role in cell survival, providing resistance to drug-induced apoptosis.
Collapse
Affiliation(s)
- Antonio R Lucena-Araujo
- Department of Internal Medicine, Medical School of Ribeirao Preto, Brazil.,Department of Genetics, Federal University of Pernambuco, Recife, Brazil
| | | | | | - Carolina Thomé
- Center for Cell Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
| | | | - Ana P Lange
- Department of Internal Medicine, Medical School of Ribeirao Preto, Brazil
| | - Helder H Paiva
- Department of Internal Medicine, Medical School of Ribeirao Preto, Brazil
| | | | - Mariana C Morais-Sobral
- Department of Microbiology, Fundação Oswaldo Cruz, Centro de Pesquisas Aggeu Magalhães, Recife, Brazil
| | - Elisa A Azevedo
- Department of Virology, Fundação Oswaldo Cruz, Centro de Pesquisas Aggeu Magalhães, Recife, Brazil
| | | | - Rafael F Franca
- Department of Virology, Fundação Oswaldo Cruz, Centro de Pesquisas Aggeu Magalhães, Recife, Brazil
| | - Cleide L Silva
- Center for Cell Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Alexandre Krause
- Department of Internal Medicine, Medical School of Ribeirao Preto, Brazil
| | - Eduardo M Rego
- Department of Internal Medicine, Medical School of Ribeirao Preto, Brazil.,Center for Cell Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
| |
Collapse
|
11
|
Furtado FM, Scheucher PS, Santana BA, Scatena NF, Calado RT, Rego EM, Matos DM, Falcão RP. Telomere length analysis in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Binet A. ACTA ACUST UNITED AC 2017; 50:e6019. [PMID: 28423121 PMCID: PMC5441285 DOI: 10.1590/1414-431x20176019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Accepted: 02/22/2017] [Indexed: 11/22/2022]
Abstract
Monoclonal B-cell lymphocytosis (MBL) is an asymptomatic clinical entity characterized by the proliferation of monoclonal B cells not meeting the diagnosis criteria for chronic lymphocytic leukemia (CLL). MBL may precede the development of CLL, but the molecular mechanisms responsible for disease progression and evolution are not completely known. Telomeres are usually short in CLL and their attrition may contribute to disease evolution. Here, we determined the telomere lengths of CD5+CD19+ cells in MBL, CLL, and healthy volunteers. Twenty-one CLL patients, 11 subjects with high-count MBL, and 6 with low-count MBL were enrolled. Two hundred and sixty-one healthy volunteers aged 0 to 88 years were studied as controls. After diagnosis confirmation, a flow cytometry CD19+CD5+-based cell sorting was performed for the study groups. Telomere length was determined by qPCR. Telomere length was similar in the 3 study groups but shorter in these groups compared to normal age-matched subjects that had been enrolled in a previous study from our group. These findings suggest that telomere shortening is an early event in CLL leukemogenesis.
Collapse
Affiliation(s)
- F M Furtado
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - P S Scheucher
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - B A Santana
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - N F Scatena
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - R T Calado
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - E M Rego
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - D M Matos
- Hospital Universitário Walter Cantidio, Faculdade de Medicina de Fortaleza, Universidade Federal do Ceará, Fortaleza, CE, Brasil
| | - R P Falcão
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| |
Collapse
|
12
|
Gutierrez-Rodrigues F, Santana-Lemos BA, Scheucher PS, Alves-Paiva RM, Calado RT. Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans. PLoS One 2014; 9:e113747. [PMID: 25409313 PMCID: PMC4237503 DOI: 10.1371/journal.pone.0113747] [Citation(s) in RCA: 113] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2014] [Accepted: 10/28/2014] [Indexed: 01/11/2023] Open
Abstract
Telomere length measurement is an essential test for the diagnosis of telomeropathies, which are caused by excessive telomere erosion. Commonly used methods are terminal restriction fragment (TRF) analysis by Southern blot, fluorescence in situ hybridization coupled with flow cytometry (flow-FISH), and quantitative PCR (qPCR). Although these methods have been used in the clinic, they have not been comprehensively compared. Here, we directly compared the performance of flow-FISH and qPCR to measure leukocytes' telomere length of healthy individuals and patients evaluated for telomeropathies, using TRF as standard. TRF and flow-FISH showed good agreement and correlation in the analysis of healthy subjects (R2 = 0.60; p<0.0001) and patients (R2 = 0.51; p<0.0001). In contrast, the comparison between TRF and qPCR yielded modest correlation for the analysis of samples of healthy individuals (R2 = 0.35; p<0.0001) and low correlation for patients (R2 = 0.20; p = 0.001); Bland-Altman analysis showed poor agreement between the two methods for both patients and controls. Quantitative PCR and flow-FISH modestly correlated in the analysis of healthy individuals (R2 = 0.33; p<0.0001) and did not correlate in the comparison of patients' samples (R2 = 0.1, p = 0.08). Intra-assay coefficient of variation (CV) was similar for flow-FISH (10.8±7.1%) and qPCR (9.5±7.4%; p = 0.35), but the inter-assay CV was lower for flow-FISH (9.6±7.6% vs. 16±19.5%; p = 0.02). Bland-Altman analysis indicated that flow-FISH was more precise and reproducible than qPCR. Flow-FISH and qPCR were sensitive (both 100%) and specific (93% and 89%, respectively) to distinguish very short telomeres. However, qPCR sensitivity (40%) and specificity (63%) to detect telomeres below the tenth percentile were lower compared to flow-FISH (80% sensitivity and 85% specificity). In the clinical setting, flow-FISH was more accurate, reproducible, sensitive, and specific in the measurement of human leukocyte's telomere length in comparison to qPCR. In conclusion, flow-FISH appears to be a more appropriate method for diagnostic purposes.
Collapse
Affiliation(s)
- Fernanda Gutierrez-Rodrigues
- Department of Internal Medicine, University of São Paulo at Ribeirão Preto School of Medicine, Ribeirão Preto, São Paulo, Brazil
- Center for Cell-based Therapy, São Paulo Research Foundation (FAPESP), Ribeirão Preto, São Paulo, Brazil
| | - Bárbara A. Santana-Lemos
- Department of Internal Medicine, University of São Paulo at Ribeirão Preto School of Medicine, Ribeirão Preto, São Paulo, Brazil
- Center for Cell-based Therapy, São Paulo Research Foundation (FAPESP), Ribeirão Preto, São Paulo, Brazil
| | - Priscila S. Scheucher
- Department of Internal Medicine, University of São Paulo at Ribeirão Preto School of Medicine, Ribeirão Preto, São Paulo, Brazil
- Center for Cell-based Therapy, São Paulo Research Foundation (FAPESP), Ribeirão Preto, São Paulo, Brazil
| | - Raquel M. Alves-Paiva
- Department of Internal Medicine, University of São Paulo at Ribeirão Preto School of Medicine, Ribeirão Preto, São Paulo, Brazil
- Center for Cell-based Therapy, São Paulo Research Foundation (FAPESP), Ribeirão Preto, São Paulo, Brazil
| | - Rodrigo T. Calado
- Department of Internal Medicine, University of São Paulo at Ribeirão Preto School of Medicine, Ribeirão Preto, São Paulo, Brazil
- Center for Cell-based Therapy, São Paulo Research Foundation (FAPESP), Ribeirão Preto, São Paulo, Brazil
- * E-mail:
| |
Collapse
|
13
|
Ferreira GA, Thome CH, dos Santos GA, Scheucher PS, Leopoldino AM, Simão AM, Izume C, Panepucci RA, Ciancaglini P, Rego EM, Faça VM, Greene LJ. Abstract A229: Mechanism of action of perifosine on the mantle cell lymphoma line, Granta-519. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-a229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Lipid rafts are highly ordered membrane domains that are enriched in cholesterol and sphingolipids and provides a scaffold for signal transduction. Altered raft assembly has been implicated in cancer progression. Alkylphospholipids have been used with promising specific cytotoxic effects in different types of cancer cells. These alkylphospholipids act by interaction with cell membranes and protein lipid rafts.
Cell viability was determined by trypan blue assay. Cell cycle was evaluated by flow cytometry. Lipid rafts were isolated using sucrose density-gradient centrifugation after 12 hours of treatment with perifosine. Antibody microarray and western blotting was used to determine levels of key cellular proteins in special on cell signaling proteins.
We showed that perifosine, an alkylphospholipid, targets raft-like domains in model membranes and induces apoptosis in mantle cell lymphomas (ED-50 20 μM - Granta-519) by activation of both extrinsic and intrinsic pathways. We observed an effect on the organization of the cell cycle, with increase of the population at G2/M phase (8,6% ± 0,6% to 27,4% ± 2,4%). Cyclin D1 decrease was detected at 24 hours of treatment. We also showed that perifosine downregulates NTAL/LAB (Non-T-cell activation linker/ Linker for activation of B-cells), an adaptor protein that is targeted to rafts by palmitoylation and specifically expressed in hematopoietic tissues. Moreover, perifosine induced a loss of NTAL/LAB in the lipid rafts of Granta-519 cells after 12 hours of treatment. Since NTAL/LAB may function as an adaptor protein in AKT signalization, we evaluate the effect of perifosine on the ATK pathway. We showed that perifosine lead to dephosphorylation of AKT and downstream components of AKT signaling. Moreover, in functional experiments, perifosine inhibited AKT activation by CD40L or IL-4 in Granta-519 cells, after few minutes of incubation, in a way similar to the specific PI3K inhibitor wortmannin. Treatment with methyl-β-cyclodextrin, a compound for cholesterol depletion, potentiated this effect. This suggests that NTAL/LAB translation is highly regulated and dependent on a functional AKT pathway. Our results indicate that perifosine acts on NTAL/LAB presumable by interference with its protein-lipid interactions and consequently AKT signaling. Our results demonstrate that a lipid raft targeting drug may present several effects on signal transduction, causing a severe toxicity to mantle cell lymphoma. Moreover, adaptor proteins like NTAL/LAB emerge as possible new therapeutic targets in lymphoma.
This research was supported by FAPESP, CNPq and CAPES.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A229.
Citation Format: Germano A. Ferreira, Carolina H. Thome, Guilherme A. dos Santos, Priscila S. Scheucher, Andreia M. Leopoldino, Ana M. Simão, Clarice Izume, Rodrigo A. Panepucci, Pietro Ciancaglini, Eduardo M. Rego, Vitor M. Faça, Lewis J. Greene. Mechanism of action of perifosine on the mantle cell lymphoma line, Granta-519. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A229.
Collapse
Affiliation(s)
| | - Carolina H. Thome
- 2National Institute of Science and Technology in Stem Cell and Cell Therapy, Ribeirão Preto, Brazil
| | | | | | | | - Ana M. Simão
- 4Faculty of Philosophy, Sciences and Languages of Ribeirão Preto - USP, Ribeirão Preto, Brazil
| | - Clarice Izume
- 1School of Medicine of Ribeirão Preto - USP, Ribeirão Preto, Brazil
| | - Rodrigo A. Panepucci
- 2National Institute of Science and Technology in Stem Cell and Cell Therapy, Ribeirão Preto, Brazil
| | - Pietro Ciancaglini
- 4Faculty of Philosophy, Sciences and Languages of Ribeirão Preto - USP, Ribeirão Preto, Brazil
| | - Eduardo M. Rego
- 1School of Medicine of Ribeirão Preto - USP, Ribeirão Preto, Brazil
| | - Vitor M. Faça
- 1School of Medicine of Ribeirão Preto - USP, Ribeirão Preto, Brazil
| | - Lewis J. Greene
- 1School of Medicine of Ribeirão Preto - USP, Ribeirão Preto, Brazil
| |
Collapse
|
14
|
Gimenes-Teixeira HL, Lucena-Araujo AR, Dos Santos GA, Zanette DL, Scheucher PS, Oliveira LC, Dalmazzo LF, Silva-Júnior WA, Falcão RP, Rego EM. Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia. Exp Hematol Oncol 2013; 2:10. [PMID: 23566596 PMCID: PMC3637292 DOI: 10.1186/2162-3619-2-10] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Accepted: 04/04/2013] [Indexed: 12/02/2022] Open
Abstract
Background CD56 expression has been associated with a poor prognosis in lymphoid neoplasms, including T-cell acute lymphoblastic leukemia (T-ALL). MicroRNAs (miRNAs) play an important role in lymphoid differentiation, and aberrant miRNA expression has been associated with treatment outcome in lymphoid malignancies. Here, we evaluated miRNA expression profiles in normal thymocytes, mature T-cells, and T-ALL samples with and without CD56 expression and correlated microRNA expression with treatment outcome. Methods The gene expression profile of 164 miRNAs were compared for T-ALL/CD56+ (n=12) and T-ALL/CD56- (n=36) patients by Real-Time Quantitative PCR. Based on this analysis, we decided to evaluate miR-221 and miR-374 expression in individual leukemic and normal samples. Results miR-221 and miR-374 were expressed at significantly higher levels in T-ALL/CD56+ than in T-ALL/CD56- cells and in leukemic blasts compared with normal thymocytes and peripheral blood (PB) T-cells. Age at diagnosis (15 or less vs grater than 15 years; HR: 2.19, 95% CI: 0.98-4.85; P=0.05), miR-221 expression level (median value as cut off in leukemic samples; HR: 3.17, 95% CI: 1.45-6.92; P=0.004), and the expression of CD56 (CD56-vs CD56+; HR: 2.99, 95% CI: 1.37-6.51; P=0.006) were predictive factors for shorter overall survival; whereas, only CD56 expression (HR: 2.73, 95% CI: 1.03-7.18; P=0.041) was associated with a shorter disease-free survival rate. Conclusions miR-221 is highly expressed in T-ALL and its expression level may be associated with a poorer prognosis.
Collapse
Affiliation(s)
- Hamilton L Gimenes-Teixeira
- Department of Internal Medicine, Division of Hematology/Oncology, University of São Paulo, Ribeirão Preto, Brazil.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Thomé CH, dos Santos GA, Ferreira GA, Scheucher PS, Izumi C, Leopoldino AM, Simão AM, Ciancaglini P, de Oliveira KT, Chin A, Hanash SM, Falcão RP, Rego EM, Greene LJ, Faça VM. Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity. Mol Cell Proteomics 2012; 11:1898-912. [PMID: 23001822 DOI: 10.1074/mcp.m112.019661] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Lipid rafts are highly ordered membrane domains rich in cholesterol and sphingolipids that provide a scaffold for signal transduction proteins; altered raft structure has also been implicated in cancer progression. We have shown that 25 μm 10-(octyloxy) decyl-2-(trimethylammonium) ethyl phosphate (ODPC), an alkylphospholipid, targets high cholesterol domains in model membranes and induces apoptosis in leukemia cells but spares normal hematopoietic and epithelial cells under the same conditions. We performed a quantitative (SILAC) proteomic screening of ODPC targets in a lipid-raft-enriched fraction of leukemic cells to identify early events prior to the initiation of apoptosis. Six proteins, three with demonstrated palmitoylation sites, were reduced in abundance. One, the linker for activation of T-cell family member 2 (LAT2), is an adaptor protein associated with lipid rafts in its palmitoylated form and is specifically expressed in B lymphocytes and myeloid cells. Interestingly, LAT2 is not expressed in K562, a cell line more resistant to ODPC-induced apoptosis. There was an early loss of LAT2 in the lipid-raft-enriched fraction of NB4 cells within 3 h following treatment with 25 μm ODPC. Subsequent degradation of LAT2 by proteasomes was observed. Twenty-five μm ODPC inhibited AKT activation via myeloid growth factors, and LAT2 knockdown in NB4 cells by shRNA reproduced this effect. LAT2 knockdown in NB4 cells also decreased cell proliferation and increased cell sensitivity to ODPC (7.5×), perifosine (3×), and arsenic trioxide (8.5×). Taken together, these data indicate that LAT2 is an early mediator of the anti-leukemic activity of alkylphospholipids and arsenic trioxide. Thus, LAT2 may be used as a target for the design of drugs for cancer therapy.
Collapse
Affiliation(s)
- Carolina H Thomé
- Instituto Nacional de Ciência e Tecnologia em Células-Tronco e Terapia Celular, Fundação Hemocentro de Ribeirão Preto, 14051-140, Ribeirão Preto, SP, Brazil
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
dos Santos GAS, Abreu e Lima RS, Pestana CR, Lima ASG, Scheucher PS, Thomé CH, Gimenes-Teixeira HL, Santana-Lemos BAA, Lucena-Araujo AR, Rodrigues FP, Nasr R, Uyemura SA, Falcão RP, de Thé H, Pandolfi PP, Curti C, Rego EM. (+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. Leukemia 2011; 26:451-60. [PMID: 21869839 DOI: 10.1038/leu.2011.216] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The vitamin E derivative (+)α-tocopheryl succinate (α-TOS) exerts pro-apoptotic effects in a wide range of tumors and is well tolerated by normal tissues. Previous studies point to a mitochondrial involvement in the action mechanism; however, the early steps have not been fully elucidated. In a model of acute promyelocytic leukemia (APL) derived from hCG-PML-RARα transgenic mice, we demonstrated that α-TOS is as effective as arsenic trioxide or all-trans retinoic acid, the current gold standards of therapy. We also demonstrated that α-TOS induces an early dissipation of the mitochondrial membrane potential in APL cells and studies with isolated mitochondria revealed that this action may result from the inhibition of mitochondrial respiratory chain complex I. Moreover, α-TOS promoted accumulation of reactive oxygen species hours before mitochondrial cytochrome c release and caspases activation. Therefore, an in vivo antileukemic action and a novel mitochondrial target were revealed for α-TOS, as well as mitochondrial respiratory complex I was highlighted as potential target for anticancer therapy.
Collapse
Affiliation(s)
- G A S dos Santos
- Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Santana BAA, Pintão MC, Abreu e Lima RS, Scheucher PS, Santos GAS, Garcia AB, Falcão RP, Rego EM. Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model. Braz J Med Biol Res 2006; 39:615-20. [PMID: 16648899 DOI: 10.1590/s0100-879x2006000500008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Acute promyelocytic leukemia (APL) is characterized by the expansion of blasts that resemble morphologically promyelocytes and harbor a chromosomal translocation involving the retinoic acid receptor alpha (RARalpha) and the promyelocytic leukemia (PML) genes on chromosomes 17 and 15, respectively. The expression of the PML/RARalpha fusion gene is essential for APL genesis. In fact, transgenic mice (TM) expressing PML/RARalpha develop a form of leukemia that mimics the hematological findings of human APL. Leukemia is diagnosed after a long latency (approximately 12 months) during which no hematological abnormality is detected in peripheral blood (pre-leukemic phase). In humans, immunophenotypic analysis of APL blasts revealed distinct features; however, the precise immunophenotype of leukemic cells in the TM model has not been established. Our aim was to characterize the expression of myeloid antigens by leukemic cells from hCG-PML/RARalpha TM. In this study, TM (N = 12) developed leukemia at the mean age of 13.1 months. Morphological analysis of bone marrow revealed an increase of the percentage of immature myeloid cells in leukemic TM compared to pre-leukemic TM and wild-type controls (48.63 +/- 16.68, 10.83 +/- 8.11, 7.4 +/- 5.46%, respectively; P < 0.05). Flow cytometry analysis of bone marrow and spleen from leukemic TM identified the asynchronous co-expression of CD34, CD117, and CD11b. This abnormal phenotype was rarely detected prior to the diagnosis of leukemia and was present at similar frequencies in hematologically normal TM and wild-type controls of different ages. The present results demonstrate that, similarly to human APL, leukemic cells from hCG-PML/RARalpha TM present a specific immunophenotype.
Collapse
MESH Headings
- Animals
- Antigens, CD/genetics
- Antigens, CD/immunology
- Bone Marrow/immunology
- Bone Marrow/pathology
- Cathepsin G
- Cathepsins
- Flow Cytometry
- Genotype
- Immunophenotyping
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/immunology
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/immunology
- Mice
- Mice, Transgenic
- Oncogene Proteins, Fusion/genetics
- Oncogene Proteins, Fusion/immunology
- Serine Endopeptidases
- Spleen/immunology
- Spleen/pathology
Collapse
Affiliation(s)
- B A A Santana
- Divisão de Hematologia e Centro de Terapia Celular, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | | | | | | | | | | | | | | |
Collapse
|